Seek Returns

Neurocrine Biosciences (NBIX) Stock Analysis

This is a peer-relative look at Neurocrine Biosciences (NBIX): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Neurocrine Biosciences (NBIX)
Profile ItemNBIX
NameNeurocrine Biosciences, Inc.
Country/RegionUnited States
GICS SectorHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
GICS Sub-IndustryBiotechnology
Market Capitalization16.66 billion USD
CurrencyUSD
ExchangeNasdaq
Listing DateMay 23, 1996
Security TypeCommon Stock

Price Performance

Cumulative Growth

NBIX
GSPC
Loading price history…
Neurocrine Biosciences (NBIX) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Neurocrine Biosciences (NBIX) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Neurocrine Biosciences (NBIX) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Neurocrine Biosciences (NBIX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: NBIXIndustry group median
Total Return (1Y)9.40%24.62%
Total Return (3Y, Annualized)14.12%20.37%
Total Return (5Y, Annualized)12.61%-4.02%

Risk Profile

Drawdown History

NBIX
GSPC
Loading price history…
Neurocrine Biosciences (NBIX) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Neurocrine Biosciences (NBIX) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Neurocrine Biosciences (NBIX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: NBIXIndustry group median
Volatility (1Y, Annualized)35.05%66.36%
Beta (5Y)0.290.93
Max Drawdown (5Y)-42.89%-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. NBIX is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Neurocrine Biosciences (NBIX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: NBIXIndustry group median
Sharpe Ratio (1Y)0.150.36
Sortino Ratio (1Y)0.220.58

Profitability

ROE (TTM)

Neurocrine Biosciences (NBIX) posts ROE of 20.42%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.42%

Group distribution
Max
109.18%
NBIX
20.42%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Largest peers
LLY
86.02%
NVS
24.33%
AZN
22.57%
NBIX
20.42%
JNJ
20.02%
MRK
5.06%
ABBV
--
Loading chart…
Where Neurocrine Biosciences (NBIX) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Neurocrine Biosciences (NBIX) keeps 18.98% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.98%

Group distribution
NBIX
18.98%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Largest peers
LLY
31.90%
NBIX
18.98%
AZN
17.68%
NVS
17.49%
JNJ
16.20%
ABBV
15.67%
MRK
3.64%
Loading chart…
Where Neurocrine Biosciences (NBIX) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Neurocrine Biosciences (NBIX) turns 31.98% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.98%

Group distribution
Max
83.12%
NBIX
31.98%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Largest peers
LLY
53.66%
ABBV
39.59%
MRK
35.22%
NVS
34.27%
NBIX
31.98%
AZN
29.57%
JNJ
25.74%
Loading chart…
Where Neurocrine Biosciences (NBIX) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Neurocrine Biosciences (NBIX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: NBIXIndustry group median
ROE (TTM)20.42%-26.66%
ROA (TTM)12.45%-12.50%
Net Margin (TTM)18.98%0.00%
Operating Margin (TTM)31.98%0.00%
Gross Margin (TTM)64.67%37.87%

Growth

Revenue Growth

Neurocrine Biosciences (NBIX) grew revenue 21.45%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

Loading chart…
Neurocrine Biosciences (NBIX): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

Neurocrine Biosciences (NBIX) grew earnings per share 41.95%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.

Loading chart…
Neurocrine Biosciences (NBIX): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

Neurocrine Biosciences (NBIX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: NBIXIndustry group median
Revenue Growth (YoY)21.45%11.45%
Revenue Growth (3Y CAGR)24.32%9.94%
EPS Growth (YoY)41.95%4.28%
EPS Growth (3Y CAGR)44.12%4.17%

Financial Strength

Current Ratio (MRQ)

Neurocrine Biosciences (NBIX) has current ratio of 2.04, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.04

Group distribution
Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
NBIX
2.04
Min
0.10
Largest peers
NBIX
2.04
LLY
1.39
MRK
1.35
JNJ
1.02
AZN
1.01
NVS
0.88
ABBV
0.87
Loading chart…
Where Neurocrine Biosciences (NBIX) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Neurocrine Biosciences (NBIX) has debt-to-equity ratio of 0.12, roughly in line with the peer group’s normal leverage range. Its mix of debt and equity looks typical for the industry.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.12

Group distribution
Max
1.42
Q3
0.65
Median
0.15
NBIX
0.12
Q1
0.02
Min
0.00
Largest peers
NVS
1.29
LLY
1.23
MRK
1.20
AZN
0.66
JNJ
0.55
NBIX
0.12
ABBV
--
Loading chart…
Where Neurocrine Biosciences (NBIX) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Neurocrine Biosciences (NBIX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: NBIXIndustry group median
Current Ratio (MRQ)2.045.52
Debt / Equity (MRQ)0.120.15
Net Debt / EBITDA-0.271.08

Dividends

Dividend Yield (TTM)

Neurocrine Biosciences (NBIX) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution
NBIX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
NVS
2.88%
ABBV
2.40%
MRK
2.29%
JNJ
1.94%
AZN
1.73%
LLY
0.49%
NBIX
0.00%
Loading chart…
Where Neurocrine Biosciences (NBIX) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Neurocrine Biosciences (NBIX) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution
NBIX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Largest peers
MRK
343.43%
ABBV
117.35%
NVS
90.46%
JNJ
80.12%
AZN
45.38%
LLY
21.71%
NBIX
0.00%
Loading chart…
Where Neurocrine Biosciences (NBIX) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Neurocrine Biosciences (NBIX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: NBIXIndustry group median
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neurocrine Biosciences (NBIX) trades at P/E ratio of 24.43, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.43

Group distribution
Max
85.34
Q3
43.46
Median
26.69
NBIX
24.43
Q1
13.30
Min
0.07
Largest peers
MRK
148.21
ABBV
50.05
LLY
43.95
JNJ
41.92
NVS
31.02
AZN
26.37
NBIX
24.43
Loading chart…
Where Neurocrine Biosciences (NBIX) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Neurocrine Biosciences (NBIX) trades at 4.50 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.50

Group distribution
Max
58.18
Q3
25.77
Median
7.30
NBIX
4.50
Q1
3.01
Min
0.01
Largest peers
LLY
13.95
ABBV
7.80
JNJ
6.69
MRK
5.37
NVS
5.35
AZN
4.63
NBIX
4.50
Loading chart…
Where Neurocrine Biosciences (NBIX) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Neurocrine Biosciences (NBIX) trades at 4.30 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

NBIX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.30

Group distribution
Max
13.53
Q3
6.54
NBIX
4.30
Median
3.25
Q1
1.69
Min
-5.59
Largest peers
LLY
29.96
NVS
8.25
JNJ
8.16
MRK
8.06
AZN
5.59
NBIX
4.30
ABBV
-112.34
Loading chart…
Where Neurocrine Biosciences (NBIX) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Neurocrine Biosciences (NBIX) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
MetricCurrent stock: NBIXIndustry group median
P/E Ratio (TTM)24.4326.69
P/S Ratio (TTM)4.507.30
P/B Ratio (MRQ)4.303.25
Free Cash Flow Yield (TTM)6.11%-1.66%